Bendamustine/Rituximab as Induction Therapy in MCL

HBI0101, an academically sourced CAR T-cell therapy, demonstrated a high objective response rate and manageable safety in patients with relapsed/refractory multiple myeloma.

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.

Belantamab mafodotin plus pomalidomide and dexamethasone showed significant progression-free survival benefits and maintained quality of life in patients with relapsed/refractory multiple myeloma, as demonstrated in the DREAMM-8 trial.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

A single infusion of the autologous GPRC5D-targeted CAR T-cell therapy BMS-986393 led to high response rates in patients with relapsed/refractory multiple myeloma who received between 1 and 3 prior lines of therapy.